Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms.

Xu B, Zheng WY, Jin DY, Ding WX, Lou WH, Ramsohok L.

World J Surg. 2011 May;35(5):1103-9. doi: 10.1007/s00268-011-1003-0.

PMID:
21416173
2.

Controversies in the management of pancreatic IPMN.

Tanaka M.

Nat Rev Gastroenterol Hepatol. 2011 Jan;8(1):56-60. doi: 10.1038/nrgastro.2010.193. Review.

PMID:
21212775
3.
4.

[Cystic tumors of the pancreas].

Grützmann R, Saeger HD.

Chirurg. 2010 Aug;81(8):755-68; quiz 769. doi: 10.1007/s00104-009-1861-2. Review. German.

PMID:
20694789
5.

Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution.

Hwang DW, Jang JY, Lee SE, Lim CS, Lee KU, Kim SW.

Langenbecks Arch Surg. 2012 Jan;397(1):93-102. doi: 10.1007/s00423-010-0674-6. Epub 2010 Jul 18.

PMID:
20640860
6.

Pancreatic cystic lesions.

Pausawasdi N, Scheiman JM.

Curr Opin Gastroenterol. 2010 Sep;26(5):506-12. doi: 10.1097/MOG.0b013e32833d115a.

PMID:
20625288
7.

CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.

Hammad N, Heilbrun LK, Philip PA, Shields AF, Zalupski MM, Venkatramanamoorthy R, El-Rayes BF.

Asia Pac J Clin Oncol. 2010 Jun;6(2):98-105. doi: 10.1111/j.1743-7563.2010.01290.x.

8.

Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes.

Wasif N, Bentrem DJ, Farrell JJ, Ko CY, Hines OJ, Reber HA, Tomlinson JS.

Cancer. 2010 Jul 15;116(14):3369-77. doi: 10.1002/cncr.25070.

9.

Incidental pancreatic cysts: do we really know what we are watching?

Correa-Gallego C, Ferrone CR, Thayer SP, Wargo JA, Warshaw AL, Fernández-Del Castillo C.

Pancreatology. 2010;10(2-3):144-50. doi: 10.1159/000243733. Epub 2010 May 17.

10.

Prognosis of cancer with branch duct type IPMN of the pancreas.

Ikeuchi N, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Kurihara T, Ishii K, Tsuji S, Umeda J, Moriyasu F, Tsuchida A, Kasuya K.

World J Gastroenterol. 2010 Apr 21;16(15):1890-5.

11.

Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas.

Poultsides GA, Reddy S, Cameron JL, Hruban RH, Pawlik TM, Ahuja N, Jain A, Edil BH, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL.

Ann Surg. 2010 Mar;251(3):470-6. doi: 10.1097/SLA.0b013e3181cf8a19.

12.

Invasive carcinoma derived from the nonintestinal type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from the intestinal type.

Sadakari Y, Ohuchida K, Nakata K, Ohtsuka T, Aishima S, Takahata S, Nakamura M, Mizumoto K, Tanaka M.

Surgery. 2010 Jun;147(6):812-7. doi: 10.1016/j.surg.2009.11.011. Epub 2010 Jan 8.

PMID:
20060146
13.

Pancreatic cysts: preoperative diagnosis and clinical management.

Pitman MB, Lewandrowski K, Shen J, Sahani D, Brugge W, Fernandez-del Castillo C.

Cancer Cytopathol. 2010 Feb 25;118(1):1-13. doi: 10.1002/cncy.20059. Review.

14.

Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas.

Ingkakul T, Sadakari Y, Ienaga J, Satoh N, Takahata S, Tanaka M.

Ann Surg. 2010 Jan;251(1):70-5. doi: 10.1097/SLA.0b013e3181c5ddc3.

PMID:
20009749
15.

International consensus guidelines for surgical resection of mucinous neoplasms cannot be applied to all cystic lesions of the pancreas.

Sawhney MS, Al-Bashir S, Cury MS, Brown A, Chuttani R, Pleskow DK, Callery MP, Vollmer CM.

Clin Gastroenterol Hepatol. 2009 Dec;7(12):1373-6. doi: 10.1016/j.cgh.2009.06.026. Epub 2009 Jul 1.

PMID:
19577006
16.

Current trends in pancreatic cystic neoplasms.

Ferrone CR, Correa-Gallego C, Warshaw AL, Brugge WR, Forcione DG, Thayer SP, Fernández-del Castillo C.

Arch Surg. 2009 May;144(5):448-54. doi: 10.1001/archsurg.2009.36.

17.

[Differentiated therapy for intraductal papillary mucinous neoplasms].

Wente MN, Schmied BM, Schmidt J, Büchler MW.

Chirurg. 2009 Jan;80(1):7-13. doi: 10.1007/s00104-008-1579-6. Review. German.

PMID:
19082569
18.

Correlation between CT patterns and pathological classification of intraductal papillary mucinous neoplasm.

Zhang J, Wang PJ, Yuan XD.

Eur J Radiol. 2010 Jan;73(1):96-101. doi: 10.1016/j.ejrad.2008.09.035. Epub 2008 Nov 12.

PMID:
19008065
19.

Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm.

Tang RS, Weinberg B, Dawson DW, Reber H, Hines OJ, Tomlinson JS, Chaudhari V, Raman S, Farrell JJ.

Clin Gastroenterol Hepatol. 2008 Jul;6(7):815-9; quiz 719. doi: 10.1016/j.cgh.2008.04.005.

PMID:
18602036
20.

Technology insight: applications of MRI for the evaluation of benign disease of the pancreas.

Kinney TP, Punjabi G, Freeman M.

Nat Clin Pract Gastroenterol Hepatol. 2007 Mar;4(3):148-59.

PMID:
17339852

Supplemental Content

Support Center